Phase 2 Clinical Study of 1095 Radiotherapy for the Treatment of Metastatic Prostate Cancer

[George71]

" Progenics' small molecule therapeutic candidate 1095 is designed to bind with high affinity to the extracellular domain of prostate specific membrane antigen (PSMA), a protein that is highly expressed in prostate cancer cells. Once bound, 1095 is internalized by the prostate cancer cells, where the beta radiation emitted by iodine-131 kills the malignant cell. This ability to deliver targeted radiation systemically to PSMA expressing cancer cells represents a novel therapeutic mechanism of action to treat prostate cancer. When studied in a compassionate use setting, 1095 markedly reduced PSA and bone pain in a group of heavily pre-treated advanced prostate cancer patients.”

globenewswire.com/news-rele...

[Fairwind]

Sounds like the race is on to get FDA approval for one of these very similar treatments.. The phase 3 "Vision" trial which is testing Lu-177 / PSMA 617 works the same way and is having encouraging results..

[tango65]

Thanks for posting.

[NPfisherman]

Thanks for posting, George....

Fish

[BruceSF]

Quick note: this study is targeted to men who don't want to do chemo (yet) and would prefer to try a lutetium-like treatment first. Also, they are expanding sites all the time, and will be in the sf bay area in a few months at Stanford and the Palo Alto VA. Watch for updates at clinicaltrials.gov/ct2/show...